The purpose of our study is to investigate CSF and blood biomarkers among the subjects with mild cognitive impairment (MCI) and Alzheimer's disease (AD) as well as normal controls.
Alzheimer's disease is the most prevalent cause of dementia. A biomarker is a variable that are measured in vivo and indicate specific features of disease related molecular mechanisms and pathologic changes, including amyloid processing and aggregation, tau hyperphosphorylation, accumulation of neurofibrillary tangles, synaptic dysfunction, neurodegeneration, and loss of brain tissue. We examine serum oligomeric beta-amyloid 42 and CSF monomeric beta-amyloid 42, total tau and phosphorylated tau, as well as PiB-PET, FDG-PET and brain MRI in 90 participants (30 normal controls, 30 patients with mild cognitive impairment, 30 patients with Alzheimer's disease).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
90
Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
Seoul National University College of Medicine, Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
RECRUITINGOligomeric beta-amyloid 42 in serum
To compare oligomeric beta-amyloid 42 in serum among normal controls, MCI and AD
Time frame: baseline
Total tau concentration in CSF
To compare total tau concentration in CSF among normal controls, MCI and AD
Time frame: baseline
Phosphorylated tau concentration in CSF
To compare phosphorylated tau concentration in CSF among normal controls, MCI and AD
Time frame: baseline
Monomeric beta-amyloid 42 in CSF
To compare monomeric beta-amyloid 42 in CSF among normal controls, MCI and AD
Time frame: baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.